AssetMark Inc’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13M | Buy |
44,277
+5,288
| +14% | +$1.5M | 0.02% | 489 |
|
|
2026
Q1 | $10.9M | Buy |
38,989
+6,224
| +19% | +$1.79M | 0.02% | 479 |
|
|
2025
Q4 | $9.93M | Buy |
32,765
+3,957
| +14% | +$1.23M | 0.02% | 499 |
|
|
2025
Q3 | $8.08M | Buy |
28,808
+7,633
| +36% | +$2.08M | 0.02% | 513 |
|
|
2025
Q2 | $5.11M | Buy |
21,175
+12,023
| +131% | +$2.84M | 0.01% | 576 |
|
|
2025
Q1 | $2.23M | Buy |
9,152
+1,242
| +16% | +$374K | 0.01% | 691 |
|
|
2024
Q4 | $2.6M | Buy |
7,910
+7,605
| +2,493% | +$2.58M | 0.01% | 650 |
|
|
2024
Q3 | $102K | Buy |
305
+140
| +85% | +$44.5K | ﹤0.01% | 1149 |
|
|
2024
Q2 | $45.1K | Sell |
165
-16,794
| -99% | -$4.88M | ﹤0.01% | 1249 |
|
|
2024
Q1 | $5.87M | Buy |
16,959
+16
| +0.1% | +$5.26K | 0.02% | 390 |
|
|
2023
Q4 | $5.47M | Sell |
16,943
-1,861
| -10% | -$583K | 0.02% | 360 |
|
|
2023
Q3 | $6.74M | Buy |
18,804
+1,246
| +7% | +$481K | 0.03% | 305 |
|
|
2023
Q2 | $6.66M | Sell |
17,558
-937
| -5% | -$381K | 0.03% | 296 |
|
|
2023
Q1 | $8.86M | Buy |
18,495
+1,380
| +8% | +$646K | 0.04% | 252 |
|
|
2022
Q4 | $7.2M | Sell |
17,115
-2,192
| -11% | -$885K | 0.03% | 256 |
|
|
2022
Q3 | $8.05M | Sell |
19,307
-113,290
| -85% | -$56.5M | 0.04% | 233 |
|
|
2022
Q2 | $65.6M | Sell |
132,597
-11,599
| -8% | -$6.04M | 0.29% | 78 |
|
|
2022
Q1 | $81.2M | Sell |
144,196
-1,576
| -1% | -$950K | 0.34% | 70 |
|
|
2021
Q4 | $110M | Buy |
145,772
+6,935
| +5% | +$5.19M | 0.45% | 55 |
|
|
2021
Q3 | $104M | Sell |
138,837
-7,253
| -5% | -$5.43M | 0.46% | 54 |
|
|
2021
Q2 | $94.1M | Buy |
146,090
+6,713
| +5% | +$4.09M | 0.44% | 54 |
|
|
2021
Q1 | $79.6M | Buy |
139,377
+8,842
| +7% | +$5.24M | 0.41% | 65 |
|
|
2020
Q4 | $76.1M | Buy |
130,535
+463
| +0.4% | +$264K | 0.42% | 67 |
|
|
2020
Q3 | $67M | Buy |
130,072
+50,096
| +63% | +$25.4M | 0.43% | 66 |
|
|
2020
Q2 | $34.6M | Buy |
79,976
+63,478
| +385% | +$28M | 0.25% | 95 |
|
|
2020
Q1 | $5.78M | Buy |
+16,498
| New | +$6.07M | 0.05% | 204 |
|
|
2019
Q1 | – | Sell |
-5
| Closed | -$1K | – | 1355 |
|
|
2018
Q4 | $1K | Sell |
5
-19
| -79% | -$5.1K | ﹤0.01% | 1276 |
|
|
2018
Q3 | $8K | Buy |
+24
| New | +$7.45K | ﹤0.01% | 1084 |
|
|
2015
Q3 | – | Sell |
-4,754
| Closed | -$716K | – | 725 |
|
|
2015
Q2 | $716K | Buy |
+4,754
| New | +$680K | 0.01% | 340 |
|
|
2015
Q1 | – | Sell |
-5
| Closed | -$1K | – | 464 |
|
|
2014
Q4 | $1K | Sell |
5
-10,541
| -100% | -$1.21M | ﹤0.01% | 465 |
|
|
2014
Q3 | $1.2M | Buy |
+10,546
| New | +$1.25M | 0.03% | 265 |
|
|
2013
Q4 | – | Sell |
-15,959
| Closed | -$1.88M | – | 394 |
|
|
2013
Q3 | $1.88M | Buy |
+15,959
| New | +$1.88M | 0.05% | 182 |
|
Other funds holding BIO
BTW
ETC
AL
SGH
PFSRSONJ
FISPB
AssetMark Inc's BIO Position: Q2 2026 in Review
AssetMark Inc increased its Bio-Rad Laboratories Class A (BIO) stake by 14% in Q2 2026, buying an estimated $1.5M and bringing the position to 44,277 shares worth $13M. The position accounts for 0.02% of the portfolio, ranked #489.
AssetMark Inc first reported a position in BIO in Q3 2013 and has held it in 32 quarters since. The position peaked at $110M in Q4 2021. 115 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- AssetMark Inc held 44,277 shares of Bio-Rad Laboratories Class A worth $13M as of Q2 2026.
- AssetMark Inc bought 5,288 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $1.5M.
- Bio-Rad Laboratories Class A made up 0.02% of AssetMark Inc's portfolio in Q2 2026, its #489 holding.
- AssetMark Inc first reported a position in Bio-Rad Laboratories Class A in Q3 2013 and has held it in 32 quarters since.
- AssetMark Inc's Bio-Rad Laboratories Class A position peaked at $110M in Q4 2021.
- 115 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.